โ Home
โน๏ธ Info
๐งพ At a Glance ๐ Core Facts ๐๏ธ Products/Services โญ Ratings ๐งโ๐ผ Executives ๐ฌ My Comments๐ก Analytics
๐ Insights ๐ข Company Q&A (574) ๐ ๏ธ Industry Q&A (121) ๐ Competitors ๐ Price Low ๐ Price Swings โก SWOT ๐๏ธ PEST ๐ Porter's Five Forces โจ Score Positive โ ๏ธ Risk Assessment ๐งฉ Segmentation ๐ ถ Google Links๐ Ratios
๐ฐ Margins ๐ Financial Ratios ๐ฑ Growth ๐ Enterprise Value ๐ Key Metrics ๐ต Dividends๐ง Tools
โ Due Diligence๐ข Press Releases
| Date | Press release |
|---|---|
| 2026-03-31 06:59:00 | Bristol Myers Squibb Evolves And Expands Standing In The Gaap To Advance More Equitable Care In Multiple Myeloma As Program Marks Ten Years Princeton, n.j.--(business wire)---- $bmy #myeloma--bristol myers squibb evolves and expands standing in the gaap to advance more equitable care in multiple myeloma as program marks ten years. |
| 2026-03-29 11:45:00 | Bristol Myers Squibb Presents Positive Results From Phase 3 Scout-hcm Trial Demonstrating Efficacy And Safety Of Camzyos (mavacamten) In Adolescents With Symptomatic Obstructive Hypertrophic Cardiomyopathy (ohcm) Princeton, n.j.--(business wire)---- $bmy #acc--bms presents positive results from phase 3 scout-hcm trial demonstrating efficacy and safety of camzyos in adolescents with symptomatic ohcm. |
| 2026-03-28 07:00:00 | Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition From Oral Atypical Antipsychotics To Cobenfyโข (xanomeline And Trospium Chloride) Princeton, n.j.--(business wire)---- $bmy #cobenfy--open label outpatient switch study demonstrates symptom stability during transition from oral atypical antipsychotics to cobenfy. |
| 2026-03-23 06:59:00 | Bristol Myers Squibb Reinforces Leadership In Ohcm With New Camzyos (mavacamten) Data At American College Of Cardiology Annual Scientific Session & Expo 2026 (acc.26) Princeton, n.j.--(business wire)---- $bmy #acc26--bms reinforces leadership in ohcm with new camzyos data at american college of cardiology annual scientific session & expo 2026 (acc.26). |
| 2026-03-20 16:42:00 | Bristol Myers Squibb Transforms The Classical Hodgkin Lymphoma Treatment Paradigm With Expanded U.s. And Ema Approvals For Opdivoยฎ (nivolumab) Princeton, n.j.--(business wire)---- $bmy #checkmate--bristol myers squibb transforms the classical hodgkin lymphoma treatment paradigm with expanded u.s. and ema approvals for opdivoยฎ (nivolumab). |
| 2026-03-19 06:59:00 |
|
| 2026-03-09 06:59:00 |
|
| 2026-03-06 21:59:00 |
|
| 2026-03-02 16:16:00 |
|
| 2026-02-26 06:59:00 |
|
| 2026-02-25 08:55:00 |
|
| 2026-02-23 16:16:00 |
|
| 2026-02-17 06:59:00 |
|
| 2026-02-09 01:00:00 |
|
| 2026-02-05 06:59:00 |
|
๐ฐ Browse additional press releases for Bristol Myers Squibb!
Sign up for free or log in๐ฅ Free eBook for new users: "The Checklist Value Investor โ A Smarter Way to Pick Stocks"